The combination of bulevirtide plus peginterferon alfa-2a is superior to bulevirtide monotherapy for achieving undetectable hepatitis D virus (HDV) RNA level at 24 weeks after the end of treatment in patients with chronic hepatitis D, according to a study published online June 6 in the New England Journal of Medicine to coincide with the annual congress of the European Association for the Study of the Liver, held from June 5 to 8 in Milan.
Data from an ongoing study in patients with compensated cirrhosis and clinically significant portal hypertension have raised hope for an emerging treatment option in this rare, deadly disease.
Ahmedabad (Gujarat) [India], May 27 (ANI): Pharmaceutical major Zydus Cadila said on Thursday its net profit jumped 73 per cent year-on-year to Rs 679 crore during the quarter ended March.
Zydus Cadila posted a 73 per cent surge in its net profit, year on year, to Rs 679 crore for the quarter ended March 31, 2021. However, the company s total income from operations grew by just three per cent to Rs 3,847 crore, from Rs 3,752 crore during corresponding period of the previous year. For the full year ended March 31, 2021, the company had a consolidated net profit of Rs 2,134 crore and total income from operations of Rs 15,102 crore. Zydus Cadila s domestic business grew 18 per cent during the quarter to Rs 1,772 crore, with the human health formulations business growing by 15 per cent while the consumer wellness business grew by 22 per cent.